# A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma

> **NCT01454479** · PHASE1 · UNKNOWN · sponsor: **Hung-Hsueh Chou** · enrollment: 24 (estimated)

## Conditions studied

- Recurrent Endometrial Cancer

## Interventions

- **DRUG:** Lapatinib and ixempra

## Key facts

- **NCT ID:** NCT01454479
- **Lead sponsor:** Hung-Hsueh Chou
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-03
- **Primary completion:** 2013-04
- **Final completion:** 2014-04
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2011-10-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01454479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01454479, "A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01454479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*